Clinical Trials

CNSEndocrineGastrointestinalNET

300 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Meningioma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04924075 2026-05-11

MK-6482-015

322 enrolled 1 FDA

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT00004847 2026-05-07

Diagnosis of Pheochromocytoma

3,000 enrolled

Endocrine

Endocrine System Diseases, Pheochromocytoma

NCT06479811 2026-04-28

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

CNSEndocrineGenitourinaryHead & Neck

120 enrolled

Head and Neck Neoplasms, Kidney Neoplasms, Paraganglioma, Pheochromocytoma

NCT03206060 2026-04-24

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

130 enrolled

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT06607692 2026-04-14

LUPARPED

25 enrolled

CNSEndocrineNETSarcoma

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT00107289 2026-04-02

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

200 enrolled

Neuroblastoma, Pheochromocytoma

NCT06041516 2026-03-27

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

70 enrolled

Neuroblastoma, Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

18 enrolled

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT06427798 2026-03-10

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

66 enrolled

Phase EARLY_PHASE1 Recruiting

Paraganglioma, Pheochromocytoma

NCT05636540 2026-02-27

In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma

30 enrolled

Paraganglioma, Pheochromocytoma

NCT07288931 2025-12-17

Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma

Phase NA Recruiting

40 enrolled

Paraganglioma, Pheochromocytoma

NCT07167329 2025-09-11

BELIEVE-VHL

CNSEndocrineGenitourinary

100 enrolled

Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma, Neuroectodermal Tumors, Primitive, Hemangioblastoma

NCT06683846 2025-08-24

Ivonescimab in the Treatment of Multiple Advanced Tumors

CNSDermatologicEndocrineGenitourinarySarcoma

400 enrolled

Urachal cancer, Carcinoma, Carcinoma, Basal Cell, Carcinoma, Transitional Cell, Kidney Neoplasms, Paget Disease, Extramammary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Prostatic Neoplasms, Rhabdomyosarcoma, Sarcoma, Angiomyolipoma, Carcinoma, Neuroendocrine, Perivascular Epithelioid Cell Neoplasms

NCT06377033 2025-07-20

Using the EHR to Advance Genomic Medicine Across a Diverse Health System

Phase NA Recruiting

1,000 enrolled

Alzheimer Disease, Paraganglioma, Parkinson Disease, Pheochromocytoma, Polyneuropathies, Aortic Aneurysm, Thoracic, Genetic Predisposition to Disease, Frontotemporal Dementia

NCT05702944 2025-06-12

The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma

Phase 4 Recruiting

24 enrolled

Paraganglioma, Pheochromocytoma

NCT05944237 2025-06-08

HTL0039732 in Participants With Advanced Solid Tumours

EndocrineGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

150 enrolled

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Pheochromocytoma, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06045260 2024-08-13

LUFOR

100 enrolled

Phase EARLY_PHASE1 Recruiting

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT05069220 2024-03-01

18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor

150 enrolled

Neuroblastoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT03344016 2020-07-09

MUPPET

Phase NA Recruiting

1,148 enrolled